Government committed to have holistic industry-friendly policies for pharma sector, says Minister Mansukh Mandaviya
Union minister for chemicals and fertilisers Dr Mansukh Mandaviya has said that the government is committed to supporting pharma companies with industry-friendly policies and investor promoting ecosystem, emphasising the importance of losing-term policies.
In an interactive session with the Indian Pharmaceutical Alliance on Saturday, he said that it is time to move from the Volume leadership to Value leadership for the Indian pharma industry to capture the global pharmaceutical market.
“This government believes in taking a holistic approach. Our policies are based on extensive and comprehensive stakeholder consultation which provide the basis for a comprehensive, long-term and vibrant policy ecosystem”.
“We need to move ahead with the pharma industry being at the forefront in taking lead and proposing their own models and initiatives in expanding manufacturing capacity, invest in innovative technologies and focus on research and development. The government will strengthen the sector through streamlining policies and effective schemes such as the PLI which support cutting edge research”.
“Let us move from ‘Volume’ to “Value’ leadership to capture the global pharmaceutical market. It is time to accumulate knowledge from global best practices in research, manufacturing and innovation and develop our own models focused on accelerating production to meet the domestic demand while increasing our global footprint,” he added.
Apart from policy front, Dr. Mandaviya also focused on the investments in research and development, efficient manufacturing capacities along with creating ample opportunities for innovation that is the need of the hour now. He was hopeful that through these steps we will be able to create a vibrant ecosystem for this sector.
S Aparna, Secretary, Department of Pharmaceuticals, said that the Government of India continues to work towards realising its goals for the pharmaceutical sector, from various initiatives aligning with the industry to sustaining focus on access, innovation, quality and affordability to help achieve India Pharma Vision 2047.
She further added that they are addressing the issue of policy stability, facilitating reforms & regulatory ease to expand manufacturing and ensure quality assessments. Government is also encouraging investment in research and development (R&D), exports and digitalization, push to incubation of new startups and entrepreneurship initiatives. She also added that review processes are being expedited and accountability is being ensured through creation of proper channels. Focusing on these factors will help us achieve growth in the pharmaceutical sector and will further build confidence in the sector.
The objective of the meeting was to discuss India’s Pharma Vision 2047 and roadmap for the Indian pharmaceutical sector. The session discussed the current position of the pharma industry in India, key initiatives taken by the government in the last few years and collaborative steps that will help India to realise this vision.
The Indian Pharmaceutical Alliance discussed and highlighted various issues such as policy stability, innovation, regulatory framework reforms and ease including transparency and accountability, review process at CDSCO, regular monitoring of implementation of schemes, pricing and associated control, investment in infrastructure aimed to give impetus to research in innovation, expansion of manufacturing capacity of chemical and API for boosting exports, digitalization to harness its potential in expanding knowledge sharing, use in medical education and increasing access to quality healthcare, and how to enrich “Brand India” through investment in start-ups and collaboration with academia for tapping best manpower.
